VRTX vs REGN: side-by-side analysis
Cross-read of VRTX (Vertex Pharmaceuticals Incorporated) versus REGN (Regeneron Pharmaceuticals Inc.): VRTX looks meaningfully undervalued at $430 versus a fair-value midpoint of $574, while REGN appears in our peer table at a forward P/E of 13.3x and ROE of 14.5%. Our current rating for VRTX is Strong Buy.
Where VRTX and REGN sit on fair value
VRTX's composite fair-value range is $428–$722 (midpoint $574), versus a current price of $430. REGN is one of VRTX's closest sector neighbours and shows up directly in the peer table inside our full report, with a market-cap of $74.9B, P/E of 13.3x, EV/EBITDA of 15.2x, and an operating margin of 20.7%. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between VRTX and REGN is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
VRTX is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. REGN, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 19.9× forward P/E with a PEG of 2.49 is not the same on VRTX as it is on REGN unless they share the same growth profile, capital intensity, and moat half-life.
VRTX's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against REGN should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: VRTX looks meaningfully undervalued versus our fair-value midpoint. The full report's peer table compares VRTX and REGN directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for VRTX is bound by the kill-scenarios list in Section 2; the equivalent for REGN would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether VRTX or REGN is the better expression of the same theme.
Bottom line — VRTX or REGN?
Our rating for VRTX is Strong Buy with a 88/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes REGN. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on VRTX, including the explicit peer multiples versus REGN and the rest of the comp set, see the canonical report at /stocks/vrtx/analysis. For REGN's standalone report, see /stocks/regn/analysis.
Frequently asked questions
VRTX vs REGN: which is cheaper today?
VRTX looks meaningfully undervalued at $430 versus a fair-value midpoint of $574 (range $428–$722). The peer table inside the full report compares VRTX and REGN directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is VRTX a better buy than REGN?
Our current rating for VRTX is Strong Buy; we do not co-rate REGN on this page — see REGN's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is VRTX?
Vertex Pharmaceuticals Incorporated is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. REGN's own archetype is in its own report.
What is VRTX's moat score versus REGN?
VRTX's moat score is 9/10. The full moat section covers source, durability, and threat timeline; REGN's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full VRTX report for the canonical evidence.